Physiomics re-engages with DoseMe for personalised dosing software

The AIM-traded firm said the collaboration aimed to provide decision support for the use of granulocyte colony-stimulating factor (GCSF), and would initially be available to selected DoseMe clients on a research basis, with plans for future paid functionality.

It said the personalised dosing software, developed with grant funding from UK bodies including Innovate UK and the National Institute for Health and Care Research, was focussed on predicting neutropenia in cancer chemotherapy patients.

By calibrating the software with early blood tests during chemotherapy, it allowed clinicians to adjust doses and foresee the impact on neutrophil levels, helping to mitigate infection and hospitalisation risks.

The renewed collaboration followed an initial partnership in late 2020, and subsequent feedback indicating the need for more modern drug focus and streamlined blood test requirements.

Following DoseMe's acquisition by a private equity group in early 2023, Physiomics re-engaged with DoseMe's new management, culminating in the planned launch of the dosing software on the upgraded DoseMeRx platform in the second half of this year.

The companies would also identify US centres with historical patient data to further enhance the software's decision-making capabilities around GCSF usage.

Additionally, Physiomics said it was aiming to make blood sampling more convenient for patients, exploring new diagnostic devices for community or home settings, developed in partnership with Beyond Blood Diagnostics.

“I'm really pleased that we've been able to progress this initiative and the team are excited to build upon the partnership with DoseMe to further develop our personalised oncology dosing software,” said chief executive officer Dr Peter Sargent.

At 0915 BST, shares in Physiomics were up 3.7% at 1.4p.

Reporting by Josh White for Sharecast.com.